Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and…

Massachusetts-based Radius Health scored an early approval Friday for Tymlos, an osteoporosis treatment for postmenopausal women. But to succeed with the drug…

Kim Kardashian is back on social media plugging for pharma. This time, the FDA might like her Instagram post better, but Instagram followers weren't so…

Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.

While some analysts aren’t thrilled by Allergan's phase 2 data for Botox in depression, the company sees enough promise to move the therapy into a wide…

Mylan faces a class action lawsuit over its pricing of allergy shot EpiPen—the first suit alleging the company violated the federal RICO Act.

Big Pharma figures the Amgen vs. Sanofi patent decision, when it comes, could upturn their pipeline drugs and development choices, so they're weighing in…

A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.

Regulatory